Cerevance to Present Phase 1 Data on CVN293, a KCNK13 Inhibitor, at AAIC 2025

Cerevance announced upcoming presentations at the Alzheimer's Association International Conference (AAIC) 2025. Key presentations include Phase 1 dat...
Home/KnloSights/Clinical Trial Updates/Cerevance to Present Phase 1 Data on CVN293, a KCNK13 Inhibitor, at AAIC 2025